MRD Directed Therapeutic Decision Making in Multiple Myeloma

In this video, “MRD Directed Therapeutic Decision Making in Multiple Myeloma”, Sagar Lonial, MD, FACP, and Saad Usmani, MD, MBA, FACP, discuss the role of minimal residual disease in MM management.

The therapeutic landscape for multiple myeloma (MM) is complex, and it continues to evolve as more treatment options become available. Several clinical trials have reported data regarding the prognostic value of minimal residual disease (MRD). Interpreting this data is a challenge, and utilizing MRD to make treatment decisions remains controversial.
Previous Article High-Risk MDS: Where We Are and Where We Are Heading
Next Article CAR-T vs. Bispecific Agents in the Treatment of Refractory Multiple Myeloma